JP2019512465A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512465A5 JP2019512465A5 JP2018544186A JP2018544186A JP2019512465A5 JP 2019512465 A5 JP2019512465 A5 JP 2019512465A5 JP 2018544186 A JP2018544186 A JP 2018544186A JP 2018544186 A JP2018544186 A JP 2018544186A JP 2019512465 A5 JP2019512465 A5 JP 2019512465A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- alkyl
- substituted
- compound according
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 80
- 125000000217 alkyl group Chemical group 0.000 claims description 47
- 125000000623 heterocyclic group Chemical group 0.000 claims description 36
- 229910052739 hydrogen Inorganic materials 0.000 claims description 36
- 239000001257 hydrogen Substances 0.000 claims description 36
- 229910052799 carbon Inorganic materials 0.000 claims description 32
- 125000003342 alkenyl group Chemical group 0.000 claims description 30
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 29
- 125000001072 heteroaryl group Chemical group 0.000 claims description 27
- 229910052760 oxygen Inorganic materials 0.000 claims description 22
- 125000000304 alkynyl group Chemical group 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 125000004450 alkenylene group Chemical group 0.000 claims description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 9
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 125000004419 alkynylene group Chemical group 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 35
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 30
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 238000003556 assay Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 2
- 108010004469 allophycocyanin Proteins 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662297450P | 2016-02-19 | 2016-02-19 | |
| US62/297,450 | 2016-02-19 | ||
| PCT/US2017/018511 WO2017143291A1 (en) | 2016-02-19 | 2017-02-17 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512465A JP2019512465A (ja) | 2019-05-16 |
| JP2019512465A5 true JP2019512465A5 (cg-RX-API-DMAC7.html) | 2020-03-26 |
| JP6956098B2 JP6956098B2 (ja) | 2021-10-27 |
Family
ID=59625486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544186A Active JP6956098B2 (ja) | 2016-02-19 | 2017-02-17 | 変異体ｐ５３機能を復元させるための方法および化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10138219B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3416638A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6956098B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102868217B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN119161324B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017221472B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3215564A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL286839B (cg-RX-API-DMAC7.html) |
| MX (1) | MX383904B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017143291A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119161324B (zh) | 2016-02-19 | 2025-10-17 | 皮姆维制药公司 | 用于恢复突变p53功能的方法和化合物 |
| FI4034104T3 (fi) | 2019-09-23 | 2025-10-08 | Pmv Pharmaceuticals Inc | Menetelmiä ja yhdisteitä mutantin p53-toiminnan palauttamiseksi |
| WO2021231474A1 (en) * | 2020-05-12 | 2021-11-18 | Pmv Pharmaceuticals, Inc. | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION |
| CN113750246B (zh) * | 2020-06-04 | 2023-12-05 | 华南理工大学 | ZIF-8纳米材料在降解广谱突变p53蛋白中的应用 |
| CN111686127B (zh) * | 2020-06-04 | 2022-02-15 | 华南理工大学 | 锌铁纳米材料在降解突变p53蛋白中的应用 |
| EP4168411A4 (en) * | 2020-06-22 | 2024-07-24 | PMV Pharmaceuticals, Inc. | METHODS AND COMPOUNDS FOR RESTORING FUNCTION IN P53 MUTANTS |
| US20230024905A1 (en) * | 2020-06-22 | 2023-01-26 | Pmv Pharmaceuticals, Inc. | Uses of p53 x-ray co-crystal structures |
| US11926632B2 (en) * | 2020-06-22 | 2024-03-12 | Pmv Pharmaceuticals, Inc. | Methods and compounds for restoring mutant p53 function |
| WO2021262483A1 (en) * | 2020-06-24 | 2021-12-30 | Pmv Pharmaceuticals, Inc. | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION |
| JP2023533447A (ja) * | 2020-06-24 | 2023-08-03 | ピーエムブイ ファーマシューティカルズ， インコーポレイテッド | がんを処置する併用療法 |
| US12419880B2 (en) * | 2020-06-24 | 2025-09-23 | Pmv Pharmaceuticals, Inc. | Companion diagnostic tool for mutant p53 reactivating compounds |
| WO2022140520A1 (en) * | 2020-12-24 | 2022-06-30 | Escient Pharmaceuticals, Inc. | Modulators of mas-related g-protein receptor x2 and related products and methods |
| WO2022213975A1 (en) * | 2021-04-08 | 2022-10-13 | Jacobio Pharmaceuticals Co., Ltd. | Compounds targeting y220c mutant of p53 |
| AU2022325357A1 (en) * | 2021-08-10 | 2024-03-07 | Jacobio Pharmaceuticals Co., Ltd. | Compounds targeting mutant of p53 |
| CN117916230A (zh) * | 2021-08-27 | 2024-04-19 | 杭州紫晶医药科技有限公司 | 作为p53调节剂的化合物 |
| EP4469043A2 (en) | 2022-01-27 | 2024-12-04 | PMV Pharmaceuticals, Inc. | Deuterated compounds for restoring mutant p53 function |
| EP4559917A1 (en) * | 2022-07-22 | 2025-05-28 | Shenzhen Zhongge Biological Technology Co., Ltd. | Compound for recovering p53 mutation function and use thereof |
| CN119968361A (zh) * | 2022-08-22 | 2025-05-09 | 北京加科思新药研发有限公司 | 靶向p53 Y220突变体的化合物 |
| CN120077047A (zh) * | 2022-10-21 | 2025-05-30 | 正大天晴药业集团股份有限公司 | 大环类化合物及其医药用途 |
| WO2024120471A1 (en) * | 2022-12-08 | 2024-06-13 | Jacobio Pharmaceuticals Co., Ltd. | Compounds targeting mutant of p53 |
| WO2025031471A1 (zh) * | 2023-08-09 | 2025-02-13 | 德睿智药(苏州)新药研发有限公司 | 用于调节p53功能的新型杂环类化合物 |
| CN119350323B (zh) * | 2023-10-20 | 2025-06-13 | 上海宇道生物技术有限公司 | 一类靶向p53突变的N-磺酰酰胺含氮稠杂环类化合物及其应用 |
| WO2025242903A1 (en) * | 2024-05-24 | 2025-11-27 | Onco3R Therapeutics Bv | Compounds and pharmaceutical compositions thereof for the treatment of proliferative diseases |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0201215A2 (en) * | 1998-12-02 | 2002-08-28 | Pfizer Prod Inc | Methods and compositions for restoring conformational stability of a protein of the p53 family |
| US6770652B2 (en) * | 2001-10-18 | 2004-08-03 | Duquesne University Of The Holy Ghost | Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same |
| WO2005051908A1 (en) * | 2003-11-25 | 2005-06-09 | Novo Nordisk A/S | Indole derivatives for use as chemical uncoupler |
| JP2008505910A (ja) | 2004-07-08 | 2008-02-28 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | Ｐｋｃ−シータのインヒビターとして有用なピリミジン誘導体 |
| WO2006136823A1 (en) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
| US8822420B2 (en) * | 2008-03-13 | 2014-09-02 | Universita Degli Studi Di Trieste | Peptides and aptamers thereof as specific modulators of mutant p53 function |
| HUE025471T2 (hu) * | 2008-04-16 | 2016-03-29 | Karobio Ab | Új ösztrogén receptor ligandumok |
| GB0808282D0 (en) * | 2008-05-07 | 2008-06-11 | Medical Res Council | Compounds for use in stabilizing p53 mutants |
| MY169311A (en) * | 2009-03-27 | 2019-03-21 | Merck Sharp & Dohme | Inhibitors of hepatitis c virus replication |
| DE102010049877A1 (de) | 2010-11-01 | 2012-05-03 | Merck Patent Gmbh | 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate |
| MX351305B (es) | 2011-01-20 | 2017-10-09 | Merck Sharp & Dohme | Antagonistas del receptor de mineralocorticoides. |
| GB201110390D0 (en) | 2011-06-20 | 2011-08-03 | Medical Res Council | Compounds for use in stabilising p53 mutants |
| US9517252B2 (en) * | 2011-09-09 | 2016-12-13 | Agency For Science, Technology And Research | p53 activating peptides |
| EP2809656A2 (en) | 2011-12-28 | 2014-12-10 | Allergan, Inc. | Benzimidazole derivatives as selective blockers of persistent sodium current |
| US8822689B2 (en) | 2012-09-19 | 2014-09-02 | Merial Limited | Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof |
| WO2015178955A1 (en) * | 2014-05-19 | 2015-11-26 | Eternity Bioscience Inc. | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors |
| WO2016004513A1 (en) * | 2014-07-11 | 2016-01-14 | Simon Fraser University | Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods |
| CN104672241B (zh) * | 2015-01-29 | 2018-04-24 | 王磊 | 吡咯并[2,3-d]嘧啶类化合物及其用途 |
| CN119161324B (zh) | 2016-02-19 | 2025-10-17 | 皮姆维制药公司 | 用于恢复突变p53功能的方法和化合物 |
-
2017
- 2017-02-17 CN CN202411302298.1A patent/CN119161324B/zh active Active
- 2017-02-17 IL IL286839A patent/IL286839B/en unknown
- 2017-02-17 JP JP2018544186A patent/JP6956098B2/ja active Active
- 2017-02-17 CA CA3215564A patent/CA3215564A1/en active Pending
- 2017-02-17 US US15/436,333 patent/US10138219B2/en active Active
- 2017-02-17 WO PCT/US2017/018511 patent/WO2017143291A1/en not_active Ceased
- 2017-02-17 CN CN201780013450.6A patent/CN109069481A/zh active Pending
- 2017-02-17 CA CA3010847A patent/CA3010847C/en active Active
- 2017-02-17 KR KR1020187026965A patent/KR102868217B1/ko active Active
- 2017-02-17 AU AU2017221472A patent/AU2017221472B2/en active Active
- 2017-02-17 MX MX2018009947A patent/MX383904B/es unknown
- 2017-02-17 EP EP17753995.4A patent/EP3416638A4/en not_active Withdrawn
-
2018
- 2018-08-15 IL IL261175A patent/IL261175B/en unknown
- 2018-10-18 US US16/163,829 patent/US10640485B2/en active Active
-
2020
- 2020-03-16 US US16/819,934 patent/US11339141B2/en active Active
-
2022
- 2022-02-24 US US17/679,568 patent/US20220213062A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512465A5 (cg-RX-API-DMAC7.html) | ||
| JP2009530424A5 (cg-RX-API-DMAC7.html) | ||
| Ranjan et al. | Recognition of HIV-TAR RNA using neomycin–benzimidazole conjugates | |
| Liu et al. | Development of small molecule inhibitors/agonists targeting STING for disease | |
| Luu et al. | A potent inhibitor of protein sequestration by expanded triplet (CUG) repeats that shows phenotypic improvements in a Drosophila model of myotonic dystrophy | |
| Huang et al. | Platinum (II) complexes containing aminophosphonate esters: Synthesis, characterization, cytotoxicity and action mechanism | |
| US20200339993A1 (en) | Aptamer Conjugates with N-Heterocyclic Carbene Metal Complexes for Targeted Drug Delivery | |
| US7872027B2 (en) | Low molecular weight Myc-max inhibitors | |
| Huang et al. | Recent trends in the development of Toll-like receptor 7/8-targeting therapeutics | |
| JP2013518036A5 (cg-RX-API-DMAC7.html) | ||
| CA2907490A1 (en) | Fluorescent-hap: a diagnostic stain for hbv cores in cells | |
| US9932333B2 (en) | Benzothiazole compound and medicine containing same | |
| WO2017037041A1 (en) | Use of indole compounds to stimulate the immune system | |
| JP2012505905A5 (cg-RX-API-DMAC7.html) | ||
| CN108853106B (zh) | 亚胺吩嗪类化合物作为狂犬病病毒抑制剂的用途 | |
| CN111936637A (zh) | 寡核苷酸官能化的疏水性聚合物纳米颗粒 | |
| JP7512409B2 (ja) | 腫瘍学及びウイルス学におけるハロゲン化キサンテンの新規の使用 | |
| Kinali-Demirci et al. | Synthesis of some novel purine derivatives incorporating tetrazole ring and investigation of their antimicrobial activity and DNA interactions | |
| CA2531869A1 (en) | Compounds having a fused, bicyclic moiety for binding to the minor groove of dsdna | |
| EP4132657A1 (en) | Compositions and methods for treatment of anticancer-drug resistant cancers | |
| EP3886850A1 (en) | Vdac inhibitors for treating inflammatory bowel diseases | |
| Zarling et al. | Cytoplasmic microinjection of immunoglobulin Gs recognizing RNA helices inhibits human cell growth | |
| CN103483239B (zh) | 吲哚满二酮缩氨基硫脲类化合物及其抗耐药菌用途 | |
| CN114907337B (zh) | 靶向cdk4或cdk6的共价抑制剂及其应用 | |
| JP2024522183A (ja) | 非標準ｇ四重鎖構造に結合する化合物ならびにそれを作製および使用する方法 |